Benjamin J. Moeller, M.D., Ph.D.

M. D. Anderson Cancer Center, Houston, Texas Residency in Radiation Oncology

The University of Texas, Houston, Houston, Texas Internship, Department of Medicine

Duke University School of Medicine, Durham, North Carolina M.D., Ph.D., Department of Pathology

Massachusetts institute of Technology, Cambridge, Massachusetts B.S., Biology and Philosophy

Trainee of the Quarter, M. D. Anderson Cancer Center

Fletcher Award for Outstanding Resident Research, M. D. Anderson Cancer Center

AAAS/Science Program for Excellence in Science nomination

American Cancer Society Institutional Student Research Fellowship

Radiation Research Society Jack Fowler Professorship Award

Howard Hughes Medical Institute Research Fellowship

Resident representative, Residency Selection Committee

Resident representative, Residency Physics Curriculum Committee

Coordinator of rotation schedules, call schedules, and clinical review curriculum

IMRT for prostate, lung, head & neck, gastrointestinal, and central nervous system cancers

Gamma Knife-based intracranial stereotactic radiosurgery

Stereotactic body radiotherapy for lung cancer and spinal metastases

Low-dose-rate brachytherapy for cervical cancer

High-dose-rate brachytherapy for endometrial cancer

Permanent interstitial brachytherapy for prostate cancer

Proton therapy for pediatric cancers

Adept with Pinnacle, Eclipse, and Mosaiq software systems

Reviewer, International Journal of Radiation Oncology Biology Physics

Reviewer, Cancer Research

1. Usami S, Abe S, Kasai M, Shinkawa H, Moeller B, Kenyon JB, Kimberling WI. Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. Laryngoscope. 107(4):483-90, 1997.

2. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R. Mutagenicity of 5-aza-2' deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci U S A. 94(9):4681-5, 1997.

3. Possemato R, Eggan K, Moeller BJ, Jaenisch R, Jackson-Grusby L. Flp recombinase regulated lacZ expression at the ROSA26 locus. Genesis. 32(2):184-6, 2002.

4. Dewhirst MW, Shan S, Cao Y, Moeller B, Yuan F, Li CV. Intravital fluorescence facilitates measurement of multiple physiologic functions and gene expression in tumors of live animals. Dis Markers. 18(5-6):293-311, 2002.

5. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood. 102(3):964-71, 2003.

6. Moeller BJ, Cao Y, Li CV, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 5(5):429-41, 2004.

7. Moeller BJ, Dewhirst MW. Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 3(9):1107-10, 2004.

8. Moeller BJ, Cao Y, Vujaskovic Z, Li CV, Haroon Z, Dewhirst MW. The relationship between hypoxia and angiogenesis. Seminars in Radiation Oncology 14(3): 215-21, 2004.

9. Sorg BS, Moeller BJ, Donovan 0, Cao Y, Dewhirst MW. Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. I Biomed Opt. 10(4):44004, 2005.

10. Moeller BJ, Dreher MR, Schroeder T, Rabbani ZN, Cao Y, Dewhirst MW. Pleiotropic effects of tumor HIF-1 blockade on radiotherapeutic sensitivity. Cancer Cell. 8(2):99-110, 2005.

11. Moeller BJ, Batinic-Haberle I, Spasojevic I, Rabbani ZN, Anscher MS, Vujaskovic Z, Dewhirst MW. A manganese porphyrin Superoxide Dismutase mimetic enhances tumor radioresponsiveness. International Journal of Radiation Oncology Biology Physics. 63(2):545-52, 2005.

12. Hart JP, Broadwaterm SG, Rabbani ZN, Moeller BJ, Clough R, Huang D, Sempowski GA, Dewhirst M, Pizzo SV, Vujaskovic Z, Anscher MS. Cytokine pro﬙ling for prediction of symptomatic radiation-induced lung injury. International Journal of Radiation Oncology Biology Physics. 63(5):1448-54, 2005.

13. Cao Y, Li CV, Moeller BJ, Yu D, Zhao Y, Dreher MR, Shan S, Dewhirst MW. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Research 65(13):5498-505, 2005.

14. Kelly P, Moeller BJ, Juneja I, Booden MA, Der CI, Daaka Y, Dewhirst MW, Fields TA, Casey PI The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Nati Acad Sci U S A. 103(21):8173-8, 2006.

15. Moeller BJ, Dewhirst MW. HIF-1 and tumour radlosensitivity. Br J Cancer 95(1):1-5, 2006.

16. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26(2):241-8, 2007.

17. Gridley DS, Makinde AY, Luo X, Rizvi A, Crapo JD, Dewhirst MW, Moeller BJ, Pearlstein RD, Slater JM. Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res. 27(5A):3101-9, 2007.

18. Zennadi R, Moeller BJ, Whalen El, Batchvarova M, Xu K, Shan S, Delahunty M, Dewhirst MW, Telen MJ. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 110(7):2708-17, 2007.

19. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller 13.1, Marks JR, Blobe GC. The type Ill IGF-beta receptor suppresses breast cancer progression. J Clin Invest. 117(1):206-17, 2007.

20. Sorg BS, Hardee ME, Agarwal N, Moeller al, Dewhirst MW. Spectral imaging facilitates visualization and measurements of unstable and abnormal microvascular oxygen transport in tumors. J Biomed Opt. 13(1):014026, 2008.

21. Gridley DS, Makinde AY, Luo X, Rizvi A, Crapo JD, Dewhirst MW, Moeller I3J, Pearlstein RD, Slater JM. Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res. 27(5A):3101-9, 2008.

22. Sarraf-Yazdi S, Mi J, Moeller MI, Niu X, White RR, Kontos CD, Sullenger BA, Dewhirst MW, Clary BM. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-speci﬙c RNA aptamer. J Surg Res. 146(1):16-23, 2008.

23. Dewhirst MW, Cao Y, Moeller W. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8(6):425-37, 2008.

24. Moeller 13.1, Pasqualini R, Arap W. Ceramide-mediated apoptosis following ionizing radiation in human prostate cancer cells: PKCalpha joins the fray. Cancer Biol Ther 8(1), 2009.

25. Moeller ELI, Pasqualini R, Arap W. Targeting cancer-specific synthetic lethality in double-strand DNA break repair. Cell Cycle 8(12): 1872-6, 2009.

26. Moeller 13.1, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank Si, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Schwartz DI_ Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 27(15): 2509-15, 2009.

27. Rabbani ZN, Spasojevic I, Zhang X, Moeller EU, Haberle S, Vasquez-Vivar J, Dewhirst MW, Vujaskovic Z, Batinic-Haberle I. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med. 47(7): 992-1004, 2009.

28. Moeller 13.1, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank Si, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DI_ Prospective imaging assessment of mortality risk following head and neck radiotherapy. International Journal of Radiation Oncology Biology Physics. Epub 2010 Feb 18.

29. Pasqualini R, Moeller 11.1, Arap W. Leveraging molecular heterogeneity of the vascular endothelium for targeted drug delivery and imaging. Sem Thromb Hemo. In press.

30. Moeller 110, Sidman RL, Pasqualini R, Arap W. DNA repair inhibitor discovery via combinatorial library profiling. In review.

1. Moeller Bi, Dreher MR, Schroeder T, Rabbani ZN, Cao Y, Dewhirst MW. Pleiotropic effects of HIF-1, blockade on tumor radiosensitivity. Radiation Research Society, 2005.

2. Moeller 13J, Cao Y, Li CV, Dewhirst MW. The role of free radicals and stress granules in radiation-induced HIF-1 activation. American Society for Therapeutic Radiology and Oncology, 2003.

3. Moeller EU, Batinic-Haberle I, Spasojevic I, Rabbani ZN, Anscher MS, Vujaskovic Z, Dewhirst MW. A Superoxide Dismutase mimetic inhibits tumor growth and vascularity. Tumor Microenvironment Workshop, 2003.

4. Moeller ELI and Dewhirst MW. Developing new targets: lessons learned from HIF-1. Invited talk. International Congress of Radiation Research, 2007.

5. Moeller 111, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee 11, Ang KK, Chao KS, Chronowski GM, Frank Si, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Schwartz DL. MG-PET/CT Imaging Does Not Impact Post-Radiation Response Assessment For Advanced Head And Neck Cancer. 7th International Conference on Head and Neck Cancer, 2008.

6. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee .1J, Ang KK, Chao KS, Chronowski GM, Frank Si, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Schwartz DI_ Does MG-PET/CT Provide Added Value Over CT Alone for Assessment of Radiation Response in Advanced Stage Head and Neck Cancer? American Society for Therapeutic Radiology and Oncology, 2008.

7. Moeller al, Cannon BA, Ang KK, Ginsberg LE, Macapinlac HA, Garden AS, Morrison WH, Rosenthal DI, Schwartz Di_ Correlating Survival with Radiographic Response to Radiotherapy for Head-and-Neck Cancer Patients: MG-PET/CT is not Superior to CT Alone. American Society for Therapeutic Radiology and Oncology, 2009.